The latest price target for Kintara Therapeutics (NASDAQ:KTRA) was reported by Maxim Group on July 14, 2023. The analyst firm set a price target for $14.00 expecting KTRA to rise to within 12 months (a possible 7787.32% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Kintara Therapeutics (NASDAQ:KTRA) was provided by Maxim Group, and Kintara Therapeutics upgraded their buy rating.

The last upgrade for Kintara Therapeutics Inc happened on July 14, 2023 when Maxim Group raised their price target to $14. Maxim Group previously had a hold for Kintara Therapeutics Inc.

The last downgrade for Kintara Therapeutics Inc happened on September 29, 2022 when Maxim Group changed their price target from N/A to N/A for Kintara Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kintara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kintara Therapeutics was filed on July 14, 2023 so you should expect the next rating to be made available sometime around July 14, 2024.

While ratings are subjective and will change, the latest Kintara Therapeutics (KTRA) rating was a upgraded with a price target of $0.00 to $14.00. The current price Kintara Therapeutics (KTRA) is trading at is $0.18, which is within the analyst’s predicted range.